Literature DB >> 14748807

Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity.

J P Donnelly1, B E De Pauw.   

Abstract

Voriconazole is a new antifungal agent that can be given orally and intravenously. It has proven efficacy for treating candidosis and invasive aspergillosis as well as other mould infections, such as those caused by Fusarium and Scedosporium spp. The drug is generally well tolerated.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14748807     DOI： 10.1111/j.1470-9465.2004.00838.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  20 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 2.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Authors:  Kim Vanstraelen; Joost Wauters; Ine Vercammen; Henriette de Loor; Johan Maertens; Katrien Lagrou; Pieter Annaert; Isabel Spriet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

4.  Development of self-forming doxorubicin-loaded polymeric depots as an injectable drug delivery system for liver cancer chemotherapy.

Authors:  Pinunta Nittayacharn; Norased Nasongkla
Journal:  J Mater Sci Mater Med       Date:  2017-05-22       Impact factor: 3.896

Review 5.  Impact of selective decontamination of the digestive tract on fungal carriage and infection: systematic review of randomized controlled trials.

Authors:  Luciano Silvestri; Hendrik K F van Saene; Marco Milanese; Dario Gregori
Journal:  Intensive Care Med       Date:  2005-05-14       Impact factor: 17.440

6.  Natamycin and Voriconazole Exhibit Synergistic Interactions with Nonantifungal Ophthalmic Agents against Fusarium Species Ocular Isolates.

Authors:  Michael E Zegans; Robert A Cramer; Christiaan A Rees; Ruina Bao
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

7.  Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors.

Authors:  Maria Simitsopoulou; Emmanuel Roilides; Fotini Paliogianni; Christodoulos Likartsis; John Ioannidis; Kalliopi Kanellou; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

Review 8.  Pharmacological properties of antifungal drugs with a focus on anidulafungin.

Authors:  Teresita Mazzei; Andrea Novelli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 9.  Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions.

Authors:  Quan Zhou; Xiao-Feng Yan; Zhong-Miao Zhang; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

10.  Comparative Study of the Effects of Fluconazole and Voriconazole on Candida glabrata, Candida parapsilosis and Candida rugosa Biofilms.

Authors:  Priya Madhavan; Farida Jamal; Chong Pei Pei; Fauziah Othman; Arunkumar Karunanidhi; Kee Peng Ng
Journal:  Mycopathologia       Date:  2018-01-29       Impact factor: 2.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.